Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930960 | 0.79 | KDM4E (0.40) | ALDH1A1KDM4EHSD17B10KMT2AMEN1 | |
| SCHEMBL2959300 | 0.76 | ALDH1A1 (0.38) | ALDH1A1CYP1A2CYP2C19KDM4EHSD17B10 | |
| SCHEMBL19212055 | 0.76 | MBOAT4 (0.40) | ALDH1A1CYP1A2CYP2C19KDM4EHSD17B10 | |
| SCHEMBL929492 | 0.75 | CCR1 (0.42) | ALDH1A1KMT2AMEN1NOTUMMAPT | |
| SCHEMBL928875 | 0.75 | ALDH1A1 (0.36) | ALDH1A1KDM4EKMT2AHPGDMAPT | |
| SCHEMBL4697306 | 0.75 | KDM4E (0.35) | ALDH1A1CYP1A2CYP2C19KDM4EHSD17B10 | |
| SCHEMBL9298287 | 0.74 | ALDH1A1 (0.42) | ALDH1A1CYP1A2CYP2C19KDM4EHSD17B10 | |
| SCHEMBL16847937 | 0.73 | AR (0.36) | ALDH1A1KDM4EHSD17B10KMT2AMEN1 | |
| SCHEMBL929809 | 0.72 | HTR2A (0.42) | ALDH1A1KDM4EHSD17B10FASNHPGD | |
| SCHEMBL2672535 | 0.71 | CYP1A2 (0.35) | ALDH1A1CYP1A2CYP2C19KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-19 | — | — | US | disclosed |
| US-9932314-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-3152199-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | Actelion Pharmaceuticals Ltd. (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-06 | — | — | US | disclosed |
| WO-2015186056-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-10 | — | — | WO | disclosed |
| US-7759369-B2 | Pyridine compounds for the treatment of prostaglandin mediated diseases | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20100137378-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| EP-2053042-A1 | Pyridine compounds for the treatment of prostaglandin mediated diseases | Glaxo Group Limited (GB) | 2009-04-29 | — | — | EP | disclosed |
| EP-1833795-B1 | PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | MARTIN PAUL GIBLIN GERARD | 2008-10-09 | — | — | US | disclosed |
| EP-1833795-A1 | PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006066968-A1 | PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | ALDH1A1 3435/4885CYP1A2 507/4885CYP2C19 400/4885 |
| US-20100137378-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | PTGER1, PTGDR, PTGER2 | ALDH1A1 2043/4885CYP1A2 241/4885CYP2C19 92/4885 |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | PTGER1, PTGDR, PTGER4 | ALDH1A1 1882/4885CYP1A2 140/4885CYP2C19 60/4885 |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | ALDH1A1 3435/4885CYP1A2 507/4885CYP2C19 400/4885 |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | ALDH1A1 3435/4885CYP1A2 507/4885CYP2C19 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.